The Australian Model: What Happens When a Country Actually Approves

“Australia approved psilocybin for treatment-resistant depression and MDMA for PTSD in February 2023. It is the only country to have done so. The implementation has revealed problems the approval process did not anticipate.”

On February 3, 2023, the Australian Therapeutic Goods Administration (TGA) amended the Poisons Standard to allow authorized psychiatrists to prescribe MDMA for post-traumatic stress disorder and psilocybin for treatment-resistant depression. Australia became the first country in the world to approve psychedelic-assisted therapy as standard of care rather than experimental intervention.

The approval created a framework: licensed psychiatrists could apply for Authorized Prescriber status from the TGA, allowing them to prescribe these substances to eligible patients outside a clinical trial. The framework required that sessions be conducted with trained therapists present and that patients receive appropriate preparation and integration support.

Implementation has been slower and more complicated than the approval announcement suggested. By mid-2024, fewer than 100 psychiatrists had received Authorized Prescriber status nationally. The compound costs, legally produced pharmaceutical-grade psilocybin and MDMA, were high: a full treatment course cost between AUD $25,000 and $35,000 per patient, with no Medicare coverage. Patients were primarily wealthy and privately funded.

A 2025 report from the Australian Healthcare and Hospitals Association identified the central equity problem: the world's first legal psychedelic therapy program was accessible almost exclusively to people with significant private means. The communities with the highest rates of treatment-resistant depression and PTSD, Aboriginal and Torres Strait Islander communities, veterans, people with histories of trauma, were the least likely to access the approved treatment.

The Australian experience is the most important policy evidence available for what happens after approval. The lesson: approval of the treatment does not solve the access problem. A regulatory framework that permits prescription by authorized psychiatrists at unsubsidized cost produces a boutique treatment for the wealthy. The Australian government is aware of this and working on Medicare coverage pathways; as of mid-2026, coverage has not been established.

For the US approval process: the Australian experience suggests that FDA approval of synthetic psilocybin psilocybin, when it comes, will produce an initial market serving a narrow population. Whether the equity framework develops from there, or whether the Australian model of expensive boutique treatment becomes the US default, is the most important downstream policy question.

Sources

• TGA Australia, MDMA and Psilocybin Approval (February 2023)
• Therapeutic Goods Administration, Authorized Prescriber Scheme Reports (2024-2025)
• Australian Healthcare & Hospitals Association, Psychedelic Therapy Implementation (2025)